Latest Myeloproliferative disease Stories
- Poster with broader update of trial results to be presented at ASCO - MISSISSAUGA, ON, May 18 /PRNewswire-FirstCall/ - YM BioSciences Inc.
MISSISSAUGA, ON, April 18 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today announced that updated interim anemia response data were reported for the first 60 patients enrolled in the Phase I/II trial of its JAK1/JAK2 inhibitor, CYT387, for the treatment of myelofibrosis.
In response to blood cancer re-classifications by the World Health Organization, the MPD Foundation announces it is changing its name to Myeloproliferative Neoplasms (MPN) Research Foundation. Chicago, IL (PRWEB) April 4, 2011 The MPD Foundation, a patient-led foundation dedicated to the discovery of treatments and a cure for three rare blood cancers (myelofibrosis, polycythemia vera, and essential thrombocythemia) announces today a new name for the organization, which will now be known as...
Over the past decade, significant advances have been made in the treatment of leukemia through the ongoing development of gene-based targeted therapies.
SINGAPORE, Dec. 6, 2010 /PRNewswire/ -- S*BIO Pte Ltd today announced that data from Phase 1/2 studies for its novel JAK2 inhibitor SB1518 indicates clinical efficacy and good tolerability for the treatment of patients with symptomatic myelofibrosis (MF) and enlarged spleens.
Company to discuss interim results from Phase I/II trial of CYT387 being presented today at the 52(nd) American Society of Hematology Annual Meeting ORLANDO, Dec. 6 /PRNewswire-FirstCall/ - YM BioSciences Inc.
Whitehead Institute researchers have shown in mouse models that overexpression of the microRNA 125b (miR-125b) can independently cause leukemia and accelerate the disease's progression.
Myeloproliferative neoplasms (MPN) comprise a family of blood cancers characterized by clonal expansion of a single blood cell type.
WHITE PLAINS, N.Y., July 12 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today announced it has awarded two new grants through its prestigious Marshall A.
SAN DIEGO, June 30 /PRNewswire/ -- TargeGen, Inc., a privately held biotechnology company focused on the development of small molecule kinase inhibitors today announced that the Company has agreed to be acquired by sanofi-aventis (EURONEXT: SAN; NYSE: SNY).
- The parings of haberdine; also, any kind of fragments.